BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neto-Ferreira R, Rocha VN, Souza-Mello V, Mandarim-de-Lacerda CA, de Carvalho JJ. Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice. Diabetol Metab Syndr. 2013;5:32. [PMID: 23816341 DOI: 10.1186/1758-5996-5-32] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Tavares TB, Santos IB, de Bem GF, Ognibene DT, da Rocha APM, de Moura RS, Resende AC, Daleprane JB, da Costa CA. Therapeutic effects of açaí seed extract on hepatic steatosis in high-fat diet-induced obesity in male mice: a comparative effect with rosuvastatin. J Pharm Pharmacol 2020;72:1921-32. [PMID: 32856322 DOI: 10.1111/jphp.13356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dajani AI, Abu Hammour AM, Zakaria MA, Al Jaberi MR, Nounou MA, Semrin AI. Essential phospholipids as a supportive adjunct in the management of patients with NAFLD. Arab J Gastroenterol. 2015;16:99-104. [PMID: 26589371 DOI: 10.1016/j.ajg.2015.09.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
3 Mohammed A, El-Bakly WM, Ali A, El-Demerdash E. Rosuvastatin improves olanzapine's effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats. Behav Brain Res 2020;378:112305. [PMID: 31634496 DOI: 10.1016/j.bbr.2019.112305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
4 Hosseini Khorami SA, Mutalib MSA, Feili Shiraz M, Abdullah JA, Rejali Z, Ali RM, Khaza'ai H. Genetic determinants of obesity heterogeneity in type II diabetes. Nutr Metab (Lond) 2020;17:55. [PMID: 32670384 DOI: 10.1186/s12986-020-00476-6] [Reference Citation Analysis]
5 Yu P, Xiong T, Tenedero CB, Lebeau P, Ni R, MacDonald ME, Gross PL, Austin RC, Trigatti BL. Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering. Arterioscler Thromb Vasc Biol 2018;38:26-39. [PMID: 29162602 DOI: 10.1161/ATVBAHA.117.305140] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
6 Wang K. Molecular mechanism of hepatic steatosis: pathophysiological role of autophagy. Expert Rev Mol Med 2016;18:e14. [PMID: 27499351 DOI: 10.1017/erm.2016.14] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol. 2016;22:91-105. [PMID: 26997214 DOI: 10.4103/1319-3767.178527] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
8 Kostapanos MS, Rizos CV, Elisaf MS. Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases. Drug Saf 2014;37:481-500. [DOI: 10.1007/s40264-014-0169-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
9 Evangelista FF, Costa-Ferreira W, Mantelo FM, Beletini LF, de Souza AH, de Laet Sant'Ana P, de Lima KK, Crestani CC, Falavigna-Guilherme AL. Rosuvastatin revert memory impairment and anxiogenic-like effect in mice infected with the chronic ME-49 strain of Toxoplasma gondii. PLoS One 2021;16:e0250079. [PMID: 33857221 DOI: 10.1371/journal.pone.0250079] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Šilhavý J, Zídek V, Landa V, Šimáková M, Mlejnek P, Škop V, Oliyarnyk O, Kazdová L, Mancini M, Saar K, Schulz H, Hübner N, Kurtz TW, Pravenec M. Rosuvastatin Can Block Pro-Inflammatory Actions of Transgenic Human C-Reactive Protein Without Reducing its Circulating Levels. Cardiovasc Ther 2014;32:59-65. [DOI: 10.1111/1755-5922.12061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
11 Kargiotis K, Athyros VG, Giouleme O, Katsiki N, Katsiki E, Anagnostis P, Boutari C, Doumas M, Karagiannis A, Mikhailidis DP. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21(25): 7860-7868 [PMID: 26167086 DOI: 10.3748/wjg.v21.i25.7860] [Cited by in CrossRef: 81] [Cited by in F6Publishing: 66] [Article Influence: 13.5] [Reference Citation Analysis]
12 Schonewille M, de Boer JF, Mele L, Wolters H, Bloks VW, Wolters JC, Kuivenhoven JA, Tietge UJ, Brufau G, Groen AK. Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice. J Lipid Res 2016;57:1455-64. [PMID: 27313057 DOI: 10.1194/jlr.M067488] [Cited by in Crossref: 72] [Cited by in F6Publishing: 38] [Article Influence: 14.4] [Reference Citation Analysis]
13 Birnbaum Y, Nanhwan MK, Ling S, Perez-Polo JR, Ye Y, Bajaj M. PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins. Cardiovasc Drugs Ther. 2014;28:447-457. [PMID: 25106875 DOI: 10.1007/s10557-014-6546-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
14 Cortese F, Gesualdo M, Cortese A, Carbonara S, Devito F, Zito A, Ricci G, Scicchitano P, Ciccone MM. Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacological Research 2016;107:1-18. [DOI: 10.1016/j.phrs.2016.02.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
15 Nishi L, Santana PL, Evangelista FF, Beletini LF, Souza AH, Mantelo FM, Souza-Kaneshima AM, Costa IN, Falavigna-Guilherme AL. Rosuvastatin reduced brain parasite burden in a chronic toxoplasmosis in vivo model and influenced the neuropathological pattern of ME-49 strain. Parasitology 2020;147:303-9. [PMID: 31727196 DOI: 10.1017/S0031182019001604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Souza-Mello V. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World J Hepatol 2015; 7(8): 1012-1019 [PMID: 26052390 DOI: 10.4254/wjh.v7.i8.1012] [Cited by in Crossref: 98] [Cited by in F6Publishing: 88] [Article Influence: 16.3] [Reference Citation Analysis]
17 Kabel AM, Elkhoely AA. Targeting proinflammatory cytokines, oxidative stress, TGF-β1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity. Biomedicine & Pharmacotherapy 2017;93:17-26. [DOI: 10.1016/j.biopha.2017.06.033] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]